SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-24-008462 to Scorpius Holdings, Inc. (SCPX) (CIK 0001476963) (SCPX)

Scorpius Holdings, Inc. (SCPX) (CIK 0001476963)
Date: July 25, 2024 · CIK: 0001476963 · Accession: 0000000000-24-008462

AI Filing Summary & Sentiment

File numbers found in text: 333-280887

Date
July 25, 2024
Author
Not clearly detected
Form
UPLOAD
Company
Scorpius Holdings, Inc. (SCPX) (CIK 0001476963)

Letter

July 25, 2024 Jeffrey Wolf Chief Executive Officer Scorpius Holdings, Inc. 627 Davis Drive, Suite 300 Morrisville, NC 27560 Re:Scorpius Holdings, Inc. Registration Statement on Form S-1 Filed July 19, 2024 File No. 333-280887 Dear Jeffrey Wolf: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Leslie Marlow, Esq.

Show Raw Text
July 25, 2024
Jeffrey Wolf
Chief Executive Officer
Scorpius Holdings, Inc.
627 Davis Drive, Suite 300
Morrisville, NC 27560
Re:Scorpius Holdings, Inc.
Registration Statement on Form S-1
Filed July 19, 2024
File No. 333-280887
Dear Jeffrey Wolf:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Leslie Marlow, Esq.